Tired But Wired: The Autonomic Betrayal at Bedtime
There is a particular cruelty that ME/CFS patients know well but rarely see described in medical literature. You are exhausted — not tired, not sleepy, but the bone-deep, cellular exhaustion of a body that has been running on empty all day. Every fibre says: sleep. Now.
You lie down. You close your eyes. And your brain turns on.
Heart rate rises instead of falling. Thoughts race — not productive thoughts, not anxiety exactly, but a buzzing, electric quality of wakefulness that cannot be turned off. The body is limp with exhaustion; the nervous system is buzzing with activation. You are simultaneously too tired to move and too wired to sleep.
This isn’t insomnia in any conventional sense, and it isn’t poor sleep hygiene. The autonomic nervous system has lost the ability to transition from its daytime mode to its nighttime mode, and everything that depends on that transition fails along with it.
1 The switch that doesn’t flip
In healthy physiology, the transition from wakefulness to sleep involves a coordinated handoff between the sympathetic nervous system (the “fight or flight” branch that dominates during the day) and the parasympathetic nervous system (the “rest and digest” branch that should dominate at night).
This handoff is actively driven by the hypothalamus, orchestrated through a cascade: declining cortisol, rising melatonin, increasing parasympathetic vagal tone, decreasing norepinephrine and epinephrine, peripheral vasodilation (to dump heat and lower core temperature), and progressive suppression of wake-promoting orexin neurons. Each step depends on the previous ones, and the full sequence takes 60–90 minutes in healthy people — the “wind-down” period that sleep hygiene advice targets.
In ME/CFS, this handoff fails at multiple points simultaneously, and the failures compound each other.
Heart rate variability studies consistently show reduced parasympathetic tone in ME/CFS, even during sleep — lower high-frequency HRV power and elevated sympathetic-to-parasympathetic ratio throughout the night (Rahman et al. 2019). The sympathetic branch simply doesn’t disengage at night — it keeps driving elevated heart rate, elevated blood pressure, and elevated norepinephrine. Physiologically, the patient’s body is in “daytime mode” while lying in a dark room at midnight.
Sustained norepinephrine carries a specific downstream consequence beyond wakefulness: it directly inhibits aquaporin-4 (AQP4) channels on astrocytes, suppressing glymphatic clearance (Xie et al. 2013). The same neurochemical that keeps the patient awake also blocks the brain’s waste-clearance system — so even when sleep eventually arrives, it arrives in a brain whose plumbing has been shut down by its own nervous system.
Then there’s the temperature problem. Sleep onset requires a ~1°C drop in core body temperature, achieved through vasodilation in the hands and feet. Autonomic dysfunction impairs exactly this vascular response. The body cannot shed heat properly, core temperature stays elevated, and the hypothalamic sleep gate doesn’t open. Patients often notice their hands and feet are cold at bedtime — which is the opposite of what should be happening, since peripheral vasoconstriction is holding heat in rather than radiating it out.
Finally, orexin regulation goes wrong. Orexin neurons in the hypothalamus are the master wake-promoting system; they should be suppressed each evening by rising sleep pressure and circadian signals. A recent integrative review of 27 studies found consistently reduced orexin-A levels overall in ME/CFS, but the temporal pattern of suppression and activation appears dysregulated in ways that produce inappropriate wakefulness at night and inappropriate sleepiness during the day (López-Amador 2025).
2 The inflammatory contribution
The autonomic failure isn’t the whole story either. Peripheral inflammatory cytokines — IL-1β, IL-6, TNF-α, elevated in many ME/CFS patients — cross into the brain via circumventricular organs and vagal afferents, where they act on hypothalamic circuits that regulate both sleep and arousal. The effect is genuinely paradoxical: these cytokines simultaneously increase sleep pressure (the brain knows the body is sick and wants to force rest) and fragment sleep architecture (the inflammatory state disrupts the oscillatory coordination needed for sustained deep sleep). This dual action — pro-somnogenic yet sleep-fragmenting — is well characterised in the cytokine-sleep literature (Krueger, Obal, and Fang 2001).
So you have inflammatory drive pushing toward sleep, while sympathetic activation and inflammatory sleep disruption prevent sleep from being restorative. Both systems are activated by the disease. They pull in opposite directions, and the patient is caught between them, exhausted and unable to rest.
3 What the night ahead looks like
If the patient eventually falls asleep — often hours after lying down — the sleep that follows bears the marks of the failed transition throughout.
Nocturnal awakenings are frequent: five to twenty or more times per night, often with full wakefulness and difficulty returning to sleep. Each awakening re-engages the sympathetic system, re-elevates norepinephrine, and resets whatever slow-wave sleep progress had been made. Healthy sleep also involves a 10–20% nocturnal dip in blood pressure, but many ME/CFS patients are “non-dippers” — their blood pressure stays elevated or even rises during sleep, a reliable marker of persistent sympathetic activation throughout the night.
The thermoregulatory instability that prevented sleep onset doesn’t resolve once sleep arrives. Mast cell degranulation releases histamine and prostaglandins that alter vascular tone unpredictably, and some patients cycle through drenching sweats and shivering chills multiple times per night, each cycle triggering an arousal that fragments sleep further. Heart rate tells the same story: instead of dropping to the 50–60 BPM typical of restful sleep, it stays at 75–90 or higher. Patients with wearables can see this directly — the overnight heart rate graph that should trace a smooth U-shaped dip instead shows a noisy, elevated plateau.
4 Why sleep hygiene advice misses the point
Standard sleep hygiene recommendations — consistent bedtime, dark room, no screens before bed, avoid caffeine — are not wrong, just insufficient. They address the behavioural and environmental factors that support the autonomic handoff, but an autonomic system that is structurally unable to make the transition will not be fixed by adjusting bedtime routines.
Telling an ME/CFS patient to “practice better sleep hygiene” for their tired-but-wired state is like telling someone with a broken thermostat to open a window. The window helps. The thermostat is still broken.
More targeted interventions exist, though none are curative and all require prescriber evaluation — especially given the autonomic comorbidities common in ME/CFS. On the autonomic side, strategies that reduce sympathetic activation — vagal nerve stimulation, slow breathing exercises if tolerated, and pharmacological approaches like low-dose clonidine or guanfacine (both cardiovascular-active agents requiring monitoring in patients with orthostatic hypotension) — address the root imbalance rather than its downstream effects. Evidence in ME/CFS is limited but mechanistically grounded.
Temperature can be manipulated directly: a warm bath 90 minutes before bed followed by cooling can artificially trigger the core temperature drop that the autonomic system isn’t providing (Haghayegh et al. 2019) (meta-analysis showing ~10-minute reduction in sleep onset latency). Some patients find that warming the extremities — heated socks, a hot water bottle at the feet — promotes the peripheral vasodilation that should be initiating sleep onset spontaneously.
For the orexin problem, dual orexin receptor antagonists (DORAs) like suvorexant and lemborexant suppress wake-promoting orexin signalling without the blunt sedation of benzodiazepines or Z-drugs. They consolidate sleep by reducing prolonged wake bouts and preserve normal sleep architecture better than older options. Early clinical experience in ME/CFS has been cautiously positive, though controlled trials are still lacking.
Circadian anchoring is worth considering separately from sedation. Low-dose melatonin (0.5–1 mg) timed to the individual’s dim-light melatonin onset — not the arbitrary “take at bedtime” instruction on the package — may help anchor the circadian phase and strengthen the evening cortisol decline. Morning bright light exposure reinforces the circadian signal from the other direction, but must be approached cautiously: for severe and very severe patients, bright light can trigger sensory overload and worsen symptoms.
5 The cost of the lost night
Every hour spent in the tired-but-wired state carries a cost that extends well beyond the next day’s exhaustion. Sustained sympathetic activation keeps norepinephrine elevated and glymphatic clearance suppressed throughout the night; delayed sleep onset eats into total slow-wave sleep; and whatever fragmented sleep does arrive disrupts memory consolidation, impairs growth hormone secretion, and leaves immune recalibration incomplete.
The bad night compounds. The patient doesn’t just feel worse the following day — there is accumulated damage from failed overnight maintenance, damage that can take days or weeks to surface as deepening brain fog, worsened pain, or a full post-exertional malaise episode triggered by activity that would have been manageable after a genuinely restorative night.
6 The legs that will not rest
Even when sleep finally arrives, the body may not cooperate.
Restless legs syndrome (RLS) and periodic limb movement disorder (PLMD) are recognised comorbidities of ME/CFS, though their ME/CFS-specific prevalence has not been rigorously studied. RLS involves an irresistible urge to move the legs, typically worse at rest and in the evening — precisely when ME/CFS patients are trying to settle into sleep. The strongest mechanistic links are to iron dysregulation (central CNS iron deficiency can occur even with normal serum iron levels) and dopaminergic dysfunction. The NIH’s deep phenotyping study found decreased cerebrospinal fluid levels of DOPA, DOPAC, and DHPG — catecholamine pathway metabolites — in ME/CFS patients versus controls (Walitt et al. 2024). A finding from a small cohort (n=17 vs. 21 controls), not yet independently replicated, but one that directly implicates the dopaminergic pathways involved in RLS.
PLMD — periodic flexion of hip and knee with dorsiflexion of the foot, occurring every 20–40 seconds during sleep — disrupts sleep architecture without the patient necessarily waking. A PLMD index above 15 events per hour is diagnostic (ICSD-3 criteria). Each movement triggers a microarousal, fragmenting sleep continuity and preventing the sustained slow-wave epochs needed for glymphatic clearance.
For ME/CFS patients, the compounding is cruel: the autonomic handoff failure delays sleep onset, RLS prevents settling, alpha-wave intrusion degrades slow-wave sleep quality once sleep arrives, and PLMD fragments whatever remains. Each mechanism independently impairs restoration; together, they can eliminate it — a nightly failure at every level from autonomic transition to motor control, feeding back into every other failure in the system.
Previous article in this series: The Nap Paradox — why rest doesn’t reset in ME/CFS.